Survival Analysis of Irish Amyotrophic Lateral Sclerosis Patients Diagnosed from 1995–2010
暂无分享,去创建一个
Ben Goldacre | Mark Heverin | Anthony Staines | Susan Byrne | Orla Hardiman | B. Goldacre | O. Hardiman | A. Staines | M. Heverin | J. Rooney | S. Byrne | B. Corr | M. Elamin | James Rooney | Bernie Corr | Marwa Elamin
[1] Mitchell H. Katz,et al. Multivariable analysis : a practical guide for clinicians and public health researchers , 2011 .
[2] O. Hardiman,et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia , 2011, Neurology.
[3] Paul C. Lambert,et al. Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model , 2011 .
[4] E. Beghi,et al. Prognostic factors in ALS: A critical review , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[5] A. Al-Chalabi,et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. , 2002, Neurology.
[6] J. Benichou,et al. Choice of time‐scale in Cox's model analysis of epidemiologic cohort data: a simulation study , 2004, Statistics in medicine.
[7] O. Hardiman,et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000 , 2003, Journal of neurology, neurosurgery, and psychiatry.
[8] O. Hardiman,et al. Incidence and prevalence of ALS in Ireland, 1995–1997 , 1999, Neurology.
[9] Matthew C. Kiernan,et al. Clinical diagnosis and management of amyotrophic lateral sclerosis , 2011, Nature Reviews Neurology.
[10] Fei Gao,et al. Age at diagnosis and the choice of survival analysis methods in cancer epidemiology. , 2003, Journal of clinical epidemiology.
[11] P. Royston,et al. Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects , 2002, Statistics in medicine.
[12] E. Beghi,et al. Predictors of long survival in amyotrophic lateral sclerosis: A population-based study , 2008, Journal of the Neurological Sciences.
[13] R. Miller,et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[14] O. Hardiman,et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. , 2000, Archives of neurology.
[15] R. Miller,et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[16] A. Arroliga,et al. Objective measures of the efficacy of noninvasive positive‐pressure ventilation in amyotrophic lateral sclerosis , 2001, Muscle & nerve.
[17] E L Korn,et al. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. , 1997, American journal of epidemiology.
[18] Tx Station. Stata Statistical Software: Release 7. , 2001 .
[19] P. Shaw,et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial , 2006, The Lancet Neurology.
[20] Yulia V. Marchenko,et al. An Introduction to Survival Analysis Using Stata, Third Edition , 2010 .
[21] G W Sun,et al. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. , 1996, Journal of clinical epidemiology.
[22] D.,et al. Regression Models and Life-Tables , 2022 .
[23] P. Lambert. STPM2: Stata module to estimate flexible parametric survival models , 2010 .
[24] V. Meininger,et al. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole , 2005, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.